Low dose of rFSH [100 IU] in controlled ovarian hyperstimulation response: a pilot study.
BACKGROUND
The initial dose of recombinant Follicle Stimulating Hormone [rFSH] to be used in assisted reproduction treatment depends on several factors, mainly the cause of the infertility and the patient's age. For young patients [≤35 years] usually an initial dose of around 150 IU of rFSH is recommended, but there are no studies proving that this should actually be the standard initial dose. We aimed to report the experience of a low-cost Human Reproduction Center where a dose of 100 IU of rFSH was used for controlled ovarian hyperstimulation [COH].


RESULTS
An observational prospective study was performed on 212 women aged ≤38 years old that underwent high-complexity assisted reproduction treatments. The patients' infertility was mainly caused by tuboperitoneal, idiopathic or male factors. Controlled ovarian stimulation was performed using 100 IU of rFSH. Regarding the COH, 53.8% of the patients presented a satisfactory response, 25.9% low response, 14.2% hyper-response, and 6.1% developed ovarian hyperstimulation syndrome. Of the 55 patients with poor response, 20 started a new cycle with an initial dose of 200 IU of rFSH; 65% showed a satisfactory response, 10% a poor response, 20% a hyper-response, and 5% developed OHSS.


CONCLUSIONS
The initial dose of 100 IU of rFSH was considered adequate for controlled ovarian hyperstimulation, meeting the aim to reduce the costs of the assisted reproduction treatment.
Caio Parente
CP
Barbosa
Emerson Barchi
EB
Cordts
Andrea Couto
AC
Costa
Renato
R
de Oliveira
Marina Acosta
MA
de Mendonça
Denise Maria
DM
Christofolini
Human Reproduction and Genetics Center, Faculdade de Medicina do ABC, Santo André, SP, Brazil. bianca.bianco@hotmail.com.
Bianca
B
Bianco
D000328:Adult; D017046:Cost Savings; D016527:Drug Costs; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D006801:Humans; D007246:Infertility / Q000175:diagnosis / Q000191:economics / Q000503:physiopathology / Q000628:therapy*; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced; D010060:Ovulation / Q000187:drug effects*; D010062:Ovulation Induction / Q000191:economics / Q000379:methods*; D010865:Pilot Projects; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
D005300:Fertility Agents, Female; D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone